» Articles » PMID: 36354703

Nomogram for Predicting Distant Metastasis of Pancreatic Ductal Adenocarcinoma: A SEER-Based Population Study

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2022 Nov 10
PMID 36354703
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: The aim of this study was to identify risk factors for distant metastasis of pancreatic ductal adenocarcinoma (PDAC) and develop a valid predictive model to guide clinical practice; (2) Methods: We screened 14328 PDAC patients from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. Lasso regression analysis combined with logistic regression analysis were used to determine the independent risk factors for PDAC with distant metastasis. A nomogram predicting the risk of distant metastasis in PDAC was constructed. A receiver operating characteristic (ROC) curve and consistency-index (C-index) were used to determine the accuracy and discriminate ability of the nomogram. A calibration curve was used to assess the agreement between the predicted probability of the model and the actual probability. Additionally, decision curve analysis (DCA) and clinical influence curve were employed to assess the clinical utility of the nomogram; (3) Results: Multivariate logistic regression analysis revealed that risk factors for distant metastasis of PDAC included age, primary site, histological grade, and lymph node status. A nomogram was successfully constructed, with an area under the curve (AUC) of 0.871 for ROC and a C-index of 0.871 (95% CI: 0.860-0.882). The calibration curve showed that the predicted probability of the model was in high agreement with the actual predicted probability. The DCA and clinical influence curve showed that the model had great potential clinical utility; (4) Conclusions: The risk model established in this study has a good predictive performance and a promising potential application, which can provide personalized clinical decisions for future clinical work.

Citing Articles

Depletion of Adipose Stroma-Like Cancer-Associated Fibroblasts Potentiates Pancreatic Cancer Immunotherapy.

Rupert J, Daquinag A, Yu Y, Dai Y, Zhao Z, Kolonin M Cancer Res Commun. 2024; 5(1):5-12.

PMID: 39620946 PMC: 11694247. DOI: 10.1158/2767-9764.CRC-24-0298.


Establishment of a nomogram model for predicting distant metastasis in pancreatic ductal adenocarcinoma: a comparative analysis of different lymph node staging systems based on the SEER database.

Liu Y, Gao M, Song Y, Wang L Sci Rep. 2024; 14(1):18136.

PMID: 39103506 PMC: 11300656. DOI: 10.1038/s41598-024-69126-8.


Development and external validation of a prognostic nomogram to predict survival in patients aged ≥60 years with pancreatic ductal adenocarcinoma.

Zheng B, Ding G, Lu G, Li L Transl Cancer Res. 2024; 13(6):2751-2766.

PMID: 38988930 PMC: 11231776. DOI: 10.21037/tcr-24-5.

References
1.
Naxerova K, Reiter J, Brachtel E, Lennerz J, van de Wetering M, Rowan A . Origins of lymphatic and distant metastases in human colorectal cancer. Science. 2017; 357(6346):55-60. PMC: 5536201. DOI: 10.1126/science.aai8515. View

2.
Wu W, He X, Yang L, Wang Q, Bian X, Ye J . Rising trends in pancreatic cancer incidence and mortality in 2000-2014. Clin Epidemiol. 2018; 10:789-797. PMC: 6042490. DOI: 10.2147/CLEP.S160018. View

3.
Singh R, OReilly E . New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs. 2020; 80(7):647-669. PMC: 7466866. DOI: 10.1007/s40265-020-01304-0. View

4.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

5.
Zhang X, Feng S, Wang Q, Huang H, Chen R, Xie Q . Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages. J Cell Mol Med. 2021; 25(3):1750-1758. PMC: 7875914. DOI: 10.1111/jcmm.16281. View